Poolbeg Pharma PLC
Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)
By Alex Langton | 13 February 2024
Elric has a financial interest in Poolbeg Pharma.
The latest announcement from Poolbeg Pharma heralds a potentially transformative juncture for the biopharmaceutical sector, especially in the niche of cancer immunotherapy-induced Cytokine Release Syndrome (CRS). With independent research backing a staggering market opportunity exceeding $10 billion for POLB 001 as a preventative therapy, the narrative is not just about the financial allure but also the significant stride towards addressing a grave unmet medical need.